망막분지정맥폐쇄에 동반된 황반부종에서 황반 허혈과 조기치료가 시력 예후에 미치는 영향

• 영문명: Effects of Macular Ischemia and Early Treatment on Visual Outcome in Branch Retinal Vein Occlusion
• 발행기관: 대한안과학회
• 저자명: 서경훈 양지호 유승영 곽형우,Kyung Hoon Seo, MD, Ji Ho Yang, MD, Seung Young Yu, MD, PhD, Hyung Woo Kwak, MD, PhD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume55,number2, 209~215쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2014.02.15

영문 초록

Purpose: To evaluate the effects of macular ischemia and early treatment on the visual outcomes of patients with branch retinal vein occlusion (BRVO). Methods: This study retrospectively reviewed the records of 42 patients who were treated with an intravitreal bevacizumab injection for BRVO, repeated 3 times at 6-week intervals and were whose data available for a follow-up period of at least 4 years. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) results before treatment and at 6, 12, 24, 36 and 48 months after the 3 serial injections, were measured. We assessed macular ischemia, time to the first treatment, and the relationship of these with BCVA. Results: Mean BCVA (log MAR) was significantly improved from 0.67 ± 0.43 at baseline to 0.30 ± 0.30 at 48 months (p < 0.001). Four years after treatment, mean BCVA in the macular non-ischemic group was better than in the ischemic group, but this relationship did not hold for mean change in BCVA. There was a statistically significant (p < 0.05) difference between the early (≤6 weeks) and late (>6 weeks) treatment groups in BCVA and mean change in BCVA after 48 months. There was statistically significant (p < 0.05) difference between the early (≤6 weeks) and late (>6 weeks) treatment groups with macular ischemia in BCVA after 48 months. Conclusions: In patients with BRVO, a significant visual improvement was maintained after intravitreal bevacizumab injections, despite the presence of macular ischemia. Early treatment (within 6 weeks) is more effective for maintaining and improving visual acuity. Similar results in the macular ischemia group confirmed the importance of early treatment. J Korean Ophthalmol Soc 2014;55(2):209-215

키워드

Bevacizumab, Branch retinal vein occlusion, Early treatment, Four-year results, Macular ischemia